leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...7273747576777879808182...235236»
  • ||||||||||  oxaliplatin / Generic mfg.
    Journal:  Oxaliplatin related multiple focal nodular hyperplasia mimicking metastasis from a gastric cancer. (Pubmed Central) -  Nov 2, 2022   
    While most multiple liver lesions in a patient with cancer will be suspicious of metastasis, a careful drug history should be obtained, as an oxaliplatin-related side effect to develop FNH has been reported. MRI with liver-specific contrast has a positive predictive value of 95% because of the biliary excretion through OATP1B3 transporter, expressed in functional hepatocytes and overexpressed in some liver tumors such as FNH, so it should be performed when FNH is suspected.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Journal, Tumor-Infiltrating Lymphocyte:  Association of Tumor-infiltrating Lymphocytes (TILs) with Survival Depends on Primary Tumor Sidedness in Stage III Colon Cancers (NCCTG N0147) [Alliance]. (Pubmed Central) -  Nov 2, 2022   
    P3
    MRI with liver-specific contrast has a positive predictive value of 95% because of the biliary excretion through OATP1B3 transporter, expressed in functional hepatocytes and overexpressed in some liver tumors such as FNH, so it should be performed when FNH is suspected. The association of TIL densities with patient survival differed by primary tumor sidedness and clinical risk group, suggesting that TILs should be interpreted in this context among stage III colon cancers.
  • ||||||||||  cabiralizumab (BMS-986227) / Ono Pharma, BMS, Opdivo (nivolumab) / BMS
    Trial completion date, Trial primary completion date:  A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) -  Nov 2, 2022   
    P2,  N=202, Active, not recruiting, 
    This study highlights the need for novel therapies to demonstrate improved patient survival compared with therapies in current clinical practice guidelines. Trial completion date: Feb 2023 --> Oct 2023 | Trial primary completion date: Aug 2022 --> Oct 2023
  • ||||||||||  5-fluorouracil / Generic mfg.
    Review, Journal, BRCA Biomarker:  Platinum-based chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): summary of evidence and application in clinical practice. (Pubmed Central) -  Nov 1, 2022   
    Trial completion date: Feb 2023 --> Oct 2023 | Trial primary completion date: Aug 2022 --> Oct 2023 (1) Selection of suitable treatment regime depends on patient performance status, comorbidities and anticipated toxicity (2) FOLFIRINOX is an appropriate treatment for patients up to 75 years of age, and with an ECOG PS of 0 or 1, without relevant comorbidities, normal or nearly normal bilirubin levels, and no significantly reduced DPD activity (3) In particular, patients with germline BRCA1/2 (gBRCA1/2) or PALB2 mutations may benefit from first-line platinum-containing therapy (4) early and comprehensive testing of the patient's mutational status could support the first-line treatment decision-making.
  • ||||||||||  methotrexate / Generic mfg.
    Review, Journal:  Overview of Methotrexate Toxicity: A Comprehensive Literature Review. (Pubmed Central) -  Nov 1, 2022   
    Leucovorin is highly beneficial in preventing myelosuppression, gastric toxicity, and neurotoxic effects after HD-MTX therapy...These patients need to be monitored, and a more gradual dosage increase and a lower weekly maximum should be considered regarding their general health situation. MTX is contraindicated in patients with RA if the eGFR is <30 mL/minute.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Identification of immune-related mechanisms of cetuximab induced skin toxicity in colorectal cancer patients. (Pubmed Central) -  Oct 28, 2022   
    Between 2014 and 2017, we prospectively enrolled 38 mCRC patients who underwent chemotherapy with either Cmab or bevacizumab (Bmab) at two hospitals...Skin rash developed in 23 (76.6%) of the 30 patients treated with Cmab plus FOLFIRI, after cycle 1...This study suggests that the inflammatory cytokine levels might be affected by Cmab exposure and are associated with the development of skin rash in mCRC patients. Further studies are warranted to evaluate this interaction in Cmab treated patients.
  • ||||||||||  Zaltrap (ziv-aflibercept IV) / Sanofi
    Trial completion date, Trial primary completion date:  Resection Observatory (clinicaltrials.gov) -  Oct 28, 2022   
    P=N/A,  N=140, Active, not recruiting, 
    In conclusion, this case highlights the clinically relevant progression-free survival with olaparib treatment in later line and the potential of better health-related quality of life in this small subset of Pancreatic cancer patients. Trial completion date: Jul 2022 --> Mar 2023 | Trial primary completion date: Jul 2022 --> Mar 2023
  • ||||||||||  oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    Trial completion, Metastases:  Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) -  Oct 28, 2022   
    P3,  N=27, Completed, 
    Trial completion date: Jul 2022 --> Mar 2023 | Trial primary completion date: Jul 2022 --> Mar 2023 Active, not recruiting --> Completed
  • ||||||||||  methotrexate IV / Generic mfg., methotrexate / Generic mfg.
    Journal:  Effects of SLCO1B1 on elimination and toxicities of high-dose methotrexate in pediatric acute lymphoblastic leukemia. (Pubmed Central) -  Oct 27, 2022   
    MTX concentration, doses of leucovorin rescue and toxicities were recorded...Moreover, SLCO1B1 polymorphisms were associated with HDMTX toxicities including thrombocytopenia, renal toxicity and anal mucositis, but not associated with MTX level at other time points or delayed elimination. Our data demonstrate that genotyping of SLCO1B1 might be useful to optimize MTX therapy.
  • ||||||||||  leucovorin calcium / Generic mfg., pyrimethamine / Generic mfg.
    Journal:  Unusual Toxoplasma infection of the eye and central nervous system in an HIV-positive patient. (Pubmed Central) -  Oct 26, 2022   
    CT and MRI scans offered no clue as to Toxoplasma etiology of the brain and eye involvement in an HIV-positive patient, which was only confirmed by laboratory tests. Due to the delay in the diagnosis of toxoplasmosis, time from the epileptic seizure to treatment initiation was 16 days, which assumedly caused irreversible blindness in the patient.
  • ||||||||||  Clinical protocol, Journal, Residual disease, Minimal residual disease:  Minimal Residual Disease-Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-US. (Pubmed Central) -  Oct 26, 2022   
    P2/3
    Due to the delay in the diagnosis of toxoplasmosis, time from the epileptic seizure to treatment initiation was 16 days, which assumedly caused irreversible blindness in the patient. CIRCULATE-US will aim to understand postoperative ctDNA dynamics in early-stage colon cancer and will investigate escalation and de-escalation approaches by using ctDNA status as a surrogate for MRD status.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
    Journal:  A Case of BRAF V600E-Mutant Colorectal Cancer Treated Effectively by Encorafenib, Binimetinib, and Cetuximab Triple Therapy (Pubmed Central) -  Oct 26, 2022   
    Transverse colostomy was performed, and FOLFOXIRI plus bevacizumab(BEV)was administered...After improvement of dermatitis, the patient resumed encorafenib plus binimetinib, improving liver metastases. Eight months after the start of the second- line, the patient has been administered with triple therapy and had stable disease status.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  A Case of Pembrolizumab Therapy Markedly Effective for Advanced Recurrent Colorectal Cancer (Pubmed Central) -  Oct 26, 2022   
    FOLFIRI plus ramucirumab therapy and FTD/TPI were introduced as the second-line and third-line treatments, respectively; however, recurrent lymph nodes were further exacerbated and showed treatment resistance...After the therapy, the lymph nodes reduced markedly. The patient remains undergoing chemotherapy without any adverse events.
  • ||||||||||  Trial completion date, Trial primary completion date, Metastases:  Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer (clinicaltrials.gov) -  Oct 26, 2022   
    P=N/A,  N=60, Recruiting, 
    The patient remains undergoing chemotherapy without any adverse events. Trial completion date: Sep 2022 --> Dec 2024 | Trial primary completion date: Jun 2022 --> Mar 2023
  • ||||||||||  irinotecan / Generic mfg.
    Retrospective data, Journal:  The efficacy of irinotecan supplementation for colorectal cancer: A meta-analysis of randomized controlled studies. (Pubmed Central) -  Oct 25, 2022   
    Arfolitixorin can easily be incorporated into current standard of care, requiring minimal changes to chemotherapy regimens. Irinotecan as the adjunctive therapy to fluorouracil and leucovorin can increase the survival and objective response of patients with colorectal cancer, but the incidence of grade ≥3 adverse events is found to be increased after irinotecan supplementation.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  Managing life-threatening 5-fluorouracil cardiotoxicity. (Pubmed Central) -  Oct 24, 2022   
    Most commonly, it is associated with coronary vasospasm secondary to direct toxic effects on vascular endothelium.A woman with metastatic colon cancer, originally treated with a 5-FU infusion as part of the FOLFIRI (Folinic acid, 5-Fluorouracil, Irinotecan) regimen, was unable to tolerate the chemotherapy due to chest pain...A multidisciplinary decision was made to again trial 5-FU infusion and pretreat with diltiazem...A multidisciplinary discussion is recommended for co-management of reversible 5-FU-associated cardiotoxicity. After coronary artery disease (CAD) risk stratification and treatment, empiric treatment with calcium channel blockers and/or nitrates may allow patients with suspected coronary vasospasm, from 5-FU, to continue this vital chemotherapy.
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
    PK/PD data, Preclinical, Journal:  FOLFIRINOX Pharmacodynamic Interactions in 2D and 3D Pancreatic Cancer Cell Cultures. (Pubmed Central) -  Oct 22, 2022   
    Here, pharmacodynamic interactions of the FOLFIRINOX agents (5-fluorouracil (5-FU), oxaliplatin (Oxa) and SN-38, the active metabolite of irinotecan) were assessed across a panel of primary and established pancreatic cancer cells...Quantitative pharmacodynamic interactions have not been described for the FOLFIRINOX regimen; this analysis suggests a complex interplay among the three chemotherapeutic agents. Extension of this pharmacodynamic analysis approach to clinical/translational studies of the FOLFIRINOX combination could reveal additional pharmacodynamic interactions and guide further refinement of this regimen to achieve optimal clinical responses.